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Abstract
Background: Prediabetes is an asymptomatic condition in which patients’ blood glucose levels are higher than
normal but do not meet diagnostic criteria for type 2 diabetes mellitus (T2DM). A key window of opportunity to
increase engagement of patients with prediabetes in strategies to prevent T2DM is when they are screened for
T2DM and found to have prediabetes, yet the effects of this screening and brief counseling are unknown.
Methods: In this parallel-design randomized controlled trial we will recruit 315 non-diabetic patients from the Ann
Arbor VA Medical Center (AAVA) who have one or major risk factors for T2DM and an upcoming primary care
appointment at the AAVA, but have not had a hemoglobin A1c (HbA1c) test to screen for T2DM in the previous
12 months. After informed consent, participants will complete a baseline survey and be randomly assigned to, at
the time of their next primary care appointment, one of two arms: (1) to have a hemoglobin A1c (HbA1c) test to
screen for T2DM and receive brief, standardized counseling about these results or (2) to review a brochure about
clinical preventive services. Participants will complete surveys 2 weeks, 3 months, and 12 months after their primary
care appointment, and a weight measurement 12 months after their primary care appointment. The primary
outcome is weight change after 12 months. The secondary outcomes are changes in perception of risk for T2DM;
knowledge of T2DM prevention; self-efficacy and motivation to prevent T2DM; use of pharmacotherapy for T2DM
prevention; physical activity; participation in weight management programs; and mental health. Quantitative
analyses will compare outcomes among participants in the HbA1c test arm found to have prediabetes with
participants in the brochure arm. Among participants in the HbA1c test arm found to have prediabetes we will
conduct semi-structured interviews about their understanding of and reactions to receiving a prediabetes diagnosis.
Discussion: This trial will generate foundational data on the effects of a prediabetes diagnosis and brief counseling
on patients’ preventive behaviors and mediators of these behaviors that will enable the development of novel
strategies to improve patient engagement in T2DM prevention.
Trial registration: ClinicalTrials.gov, NCT02747108. Registered on 18 April 2016.
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Background
Prediabetes is an asymptomatic condition in which
patients’ blood glucose levels are higher than normal
but not high enough to meet diagnostic criteria for
type 2 diabetes mellitus (T2DM). The American
Diabetes Association (ADA) defines prediabetes as
either fasting plasma glucose of 100 to 125 mg/dL,
2-hour plasma glucose of 140 to 199 mg/dL after a
75-g oral glucose tolerance test, or hemoglobin A1c
(HbA1c) of 5.7 to 6.4% [1]. Currently 38% of adults
in the USA have prediabetes [2], which is associated
with an approximately threefold greater annual inci-
dence of T2DM [3] and an approximately 50% greater
risk of cardiovascular disease [4–6].
Fortunately, patients with prediabetes can signifi-
cantly reduce their risk of developing T2DM through
weight loss, physical activity, or pharmacotherapy [7,
8]. The landmark Diabetes Prevention Program (DPP)
trial demonstrated that a lifestyle-modification pro-
gram with the goals of at least 7% weight loss and at
least 150 minutes of physical activity per week led to
a 58% reduction in the 3-year incidence of T2DM [9].
This was significantly greater than the 31% reduction
in the incidence of T2DM that was observed among
patients who received metformin 850 mg by mouth
twice daily, but progression to T2DM with metformin
was still significantly less than the rate of progression
in the control group. Due to the effectiveness [8] and
cost-effectiveness [10] of these interventions, a num-
ber of studies have translated the DPP for use in
different populations [11]. Moreover, the National
DPP, an initiative led by the US Centers for Disease
Control and Prevention, is currently working to dis-
seminate and implement the DPP in communities
across the USA [12].
Importance of patient engagement in diabetes prevention
While there are defined ways to identify patients with
prediabetes and evidence-based strategies to prevent or
delay their progression to T2DM, the real-world execu-
tion of these strategies relies heavily on patient engage-
ment. Specifically, in order for patients with prediabetes
to engage in interventions to prevent or delay T2DM
they must: (1) believe they have an elevated but modifi-
able risk of T2DM; (2) be motivated to prevent T2DM;
(3) understand strategies they could use to prevent
T2DM and be motivated to engage in these strategies;
and (4) have the self-efficacy and support needed to sustain
these behaviors. These goals are often difficult for at-risk
patients to achieve, as evidenced by widespread lack of
awareness of a prediabetes diagnosis, [13] frequent under-
estimation of risk of T2DM [14], and low rates of en-
gagement in behaviors to prevent T2DM [15–17].
Screening for diabetes as a window of opportunity for
diabetes prevention
A key opportunity to increase patients’ engagement in
evidence-based strategies to prevent T2DM is when they
are informed at a primary care appointment that they
have prediabetes. This process is depicted in the concep-
tual model shown in Fig. 1, which incorporates key do-
mains from relevant health behavior theories such as the
health belief model [18] and the transtheoretical model
[19]. This process of informing patients that they have
prediabetes usually starts with a screening laboratory
test for T2DM. Patients whose laboratory test results are
in the prediabetes range should then be informed by
their provider that they have prediabetes and educated
about how they can prevent or delay the onset of T2DM
by: (1) losing weight and increasing physical activity, (2)
participating in an evidence-based weight management
Fig. 1 Conceptual model of patient engagement in behaviors recommended for the prevention of type 2 diabetes mellitus (T2DM). HbA1c hemoglobin A1c
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program like the DPP; or (3) starting metformin [20]. At
this critical stage, patients then should decide whether
to engage in any behavior to reduce their risk for T2DM
and, if so, which strategy or strategies to pursue.
Qualitative research from the UK suggests that this
process of informing patients that they have prediabetes
represents a highly “teachable moment” during which
patients reflect on their risk of developing T2DM and
form their motivation to reduce this risk [21, 22]. While
this research indicates that the content of information
given to patients when they are identified as having predi-
abetes is important, it also points to ways in which subtle
factors may shape patient engagement. For example, the
speed with which patients receive their screening test re-
sults, the source of those results (e.g., physician or ancil-
lary provider), and the clarity of recommendations on
behavior change may each impact the inferences patients
draw about their risk of developing T2DM and their sub-
sequent decisions to engage in behaviors to prevent
T2DM [21, 22]. Despite the promise of this process of
screening for T2DM to increase patients’ perception of
their risk of T2DM, their motivation and self-efficacy to
prevent T2DM, and their efforts to modify risk factors for
T2DM such as excess weight and lack of physical activity,
the effects of a prediabetes diagnosis and brief counseling
on these factors remain undefined [21, 23–25]. The objec-
tives of this parallel-design randomized controlled trial
(RCT) are to determine the effects of a prediabetes diag-
nosis and brief counseling on weight change; to examine
the effects of a prediabetes diagnosis and brief counseling
on engagement in behaviors to prevent T2DM and media-
tors of these behaviors; and to gain deep insights into pa-




We will recruit 315 non-diabetic patients from the Ann
Arbor VA Medical Center (AAVA), who have an upcoming
primary care appointment at the AAVA and one or more
major risk factors for T2DM, but have not had an HbA1c
test to screen for T2DM in the previous 12 months. The
full inclusion and exclusion criteria are shown in Table 1.
Patients who meet preliminary eligibility criteria based
on AAVA administrative data will be mailed a study in-
formation packet that describes the study and provides
them with contact information to inquire further or opt
out of being contacted about the study. After 10 days of
mailing the letter, a Research Assistant who is blinded to
the allocation sequence will call these preliminarily eligible
patients to elicit their interest in study participation. For pa-
tients who are interested in participating, eligibility criteria
that could not be assessed through AAVA administrative
data will be evaluated through a brief set of additional
screening questions. If at the end of this call the patient is
eligible to participate, they will be asked to sign and return
the informed consent form that had been mailed to them
in their initial study information packet.
Randomization and study arms
After giving informed consent, the 315 enrolled patients
will each complete a baseline survey. Then approxi-
mately 2 weeks before their primary care appointment,
each patient will be randomly assigned to one of two
study groups in a 4:1 ratio (252 to the HbA1c test and
brief counseling arm and 63 to the clinical preventive
brochure arm) using blocked randomization with
variable block lengths. The allocation sequence will be
determined using computer-generated random numbers
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteriaa Exclusion Criteria
• Receives primary care at the Ann Arbor VA Medical Center • Age >75 yearsa
• BMI ≥30 kg/m2 or
• BMI ≥25 kg/m2 with any of the following:
• Type 1 diabetesa,b (ICD-9 250 or ICD-10 E10.9)
• Hypertension (ICD-9 401 or ICD-10 I10) • Type 2 diabetesa,b (ICD-9 250 or ICD-10 E11)
• Hyperlipidemia (ICD-9 272.4 or ICD-10 E78.5) • Dementiaa (ICD-9 290 or ICD-10 F03)
• Hypoalphalipoproteinemia (ICD-9 272.5 or ICD-10 E78.6) • End-stage renal diseasea,b (ICD-9 585.6 or ICD-10 N18.6)
• Coronary artery disease (ICD-9 414.01 or ICD-10 I25.119) • Severe chronic obstructive pulmonary disease (ICD-9 496 or ICD-10 J44)a,b
• Peripheral vascular disease (ICD-9 443.9 or ICD-10 I73.9) • Receiving chemotherapyb
• Hypertriglyceridemia (ICD-9 272.1 or ICD-10 E78.1) • New York Heart Association Class III or IV congestive heart failure
(ICD-9 428 or ICD-10 I50.20 or ICD-10 I50.30)a,b
• Past HbA1c of 5.7 - 6.4 • Pregnant or planning to become pregnant in the next yearb
• Impaired fasting glucose (ICD-9 790.21 or ICD-10 R73.01) • Stroke or myocardial infarction in the past 6 monthsb
• Impaired glucose tolerance (ICD-9 790.22 or ICD-10 R73.02) • Cirrhosis (ICD-9 571 or ICD-10 K74.60)a
• Polycystic ovary syndrome (ICD-9 256.4 or ICD-10 E28.2) • HbA1c test in the past 12 monthsa
aData obtained from the VA Corporate Data Warehouse. bData obtained from a telephone screening survey administered to patients who are preliminarily eligible based on
data from the VA Corporate Data Warehouse. HbA1c hemoglobin A1c
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and will be concealed in a password-protected file until
study groups are assigned. We chose this 4:1 allocation
ratio because in our main analyses we will compare
patients in the HbA1c test and brief counseling arm,
whose HbA1c is in the prediabetes range to patients in
the clinical preventive service brochure arm, and we
anticipate that 20% of patients in the HbA1c test and
brief counseling arm (i.e., 63 of 252 patients) will have
HbA1c in the prediabetes range. All arm assignments
will be communicated to patients by phone and a
mailed letter, after which patients and Research Assis-
tants will no longer be blinded to the arm assignment,
but data analysts will continue to be blinded. Through-
out the subsequent 12 months of the study patients in
both arms will continue to receive usual care through
their VA primary care team, which at the AAVA typic-
ally includes routine offers of a referral to the VA
weight management program (MOVE) for patients who
are overweight or obese.
HbA1c test and brief counseling arm
The 252 patients who are randomly assigned to the
HbA1c test and brief counseling arm will be asked to
have an HbA1c test to screen for T2DM at the AAVA
outpatient laboratory. We will then interpret these
HbA1c results and group them into the following
categories based on American Diabetes Association
(ADA) [26] and National DPP [12] guidelines:
 HbA1c <5.7% = normal (i.e., neither prediabetes nor
T2DM)
 HbA1c ≥5.7% and <6.5% = prediabetes
 HbA1c ≥6.5% = T2DM
These HbA1c results will be immediately communi-
cated to and interpreted for each patient’s VA primary
care physician in a brief note in the VA Computerized
Patient Record System (CPRS). Within 2 weeks of their
primary care appointment, a Research Assistant will pro-
vide to the patient standardized brief phone counseling
about their HbA1c result (Additional file 1), and will
mail to the patient a summary of this standardized brief
counseling (Additional file 2). These processes will pro-
vide patients and physicians with an opportunity to dis-
cuss the HbA1c result and make plans for follow-up
information and support, yet will ensure that all patients
will receive their HbA1c result within 2 weeks of the
test, in accordance with VA standards.
In this standardized brief counseling and mailed infor-
mation, patients whose HbA1c is in the normal range
will simply be informed of this result. Patients whose
HbA1c is in the prediabetes range will receive counsel-
ing and information based on the VA/Department of
Defense guidelines for prevention of T2DM and will
emphasize the risk of progression to T2DM and the
rationale for preventive strategies, encourage aerobic
exercise and a calorie-restricted diet to promote and
maintain weight loss, set a goal of achieving and sustain-
ing weight loss of at least 7% of body weight, and note
pharmacotherapy as an option for preventing or delaying
T2DM. Patients whose HbA1c is in the T2DM range
will be told their HbA1c indicates they may have T2DM
and will soon be contacted by their primary care team
for follow up.
Clinical preventive service brochure arm
The 63 patients who are randomized to the clinical
preventive service brochure arm will not have a
screening HbA1c test ordered through the study. In-
stead, these patients will receive usual care and be
mailed a brochure from the VA National Center for
Health Promotion and Disease Prevention with gen-
eral information about the value of clinical preventive
services such as screenings and immunizations. These
patients will be asked to review this information
around the time of their primary care appointment.
The brochure will be summarized for each patient’s
VA primary care physician in a brief VA CPRS note.
Within 2 weeks of their primary care appointment, a
Research Assistant will call the patient to provide
standardized brief counseling based on the informa-
tion in the brochure. In this way, patients in the clin-
ical preventive service brochure arm will spend an
approximately equal amount of time receiving and
reviewing information related to prevention as pa-
tients randomized to the HbA1c test and brief coun-




Patients will complete four surveys: (1) at baseline (i.e.,
before randomization); (2) within 2 weeks of receiving
the HbA1c test results or the clinical preventive service
brochure; (3) at 3 months after receiving the HbA1c test
results or the clinical preventive service brochure; and
(4) at 12 months after receiving the HbA1c test results
or the clinical preventive service brochure (Fig. 2).
Patients will be able to complete and submit each
survey online (via Qualtrics), by mail, in person, or by
telephone. Data from mailed, in person, and telephone
surveys will be entered into Qualtrics. The measures
contained in each survey are shown in Table 2. For com-
pletion of each survey, patients will receive a US$10 gift
card. All survey data will be stored in password protected
files on a secure server.
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Semi-structured interviews among patients with prediabetes
To gain deeper understanding of patient perceptions of
a prediabetes diagnosis and brief counseling, we will
conduct semi-structured telephone interviews among a
maximum variation purposive sample of patients who
are newly diagnosed with prediabetes and have different
levels of health literacy. We will focus on health literacy
because of its strong relationship to patients’ self-care
behaviors, receipt of recommended preventive services,
understanding of health information, and health out-
comes [27]. We will conduct the interviews by phone to
minimize participant burden and maximize the response
rate. These participants will be invited to participate in
the interview approximately 6 months after their
HbA1c tests. Interviews will consist of open-ended
questions to elicit feelings about receiving a predia-
betes diagnosis, understanding of prediabetes and
behavioral recommendations, facilitators of and bar-
riers to behavior change, and uncertainties about hav-
ing prediabetes. Each interview will be audio-recorded
and transcribed verbatim, and we will stop conducting
interviews when we reach thematic saturation. All
interview data will be stored in password-protected
files on a secure server.
Outcomes
The primary outcome is weight change 12 months after
receipt of HbA1c test results or the clinical preventive
service brochure. The secondary outcomes will be
changes in self-reported use of medication for preven-
tion of T2DM, participation in a weight management
program, perception of risk for T2DM, knowledge of
strategies to prevent T2DM, motivation to prevent
T2DM, self-efficacy to engage in behaviors to prevent
Fig. 2 Schedule of enrollment, interventions, and assessments. T2DM type 2 diabetes mellitus, HbA1c hemoglobin A1c
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T2DM, physical activity, and mental health. We will not
measure progression from prediabetes to T2DM because
participants in the clinical preventive service brochure
arm will not have an HbA1c test as part of the study.
Sample size calculation
Our main comparisons of interest are between outcomes
for patients who receive a prediabetes diagnosis in the
HbA1c test and brief counseling arm and outcomes for
patients in the clinical preventive service brochure arm.
Using α of 0.05, 56 patients who receive a prediabetes
diagnosis in the HbA1c test and brief counseling arm
and 56 patients in the clinical preventive service
brochure arm will provide 80% power to detect a statisti-
cally significant difference between a projected mean
12-month weight change of -9.9 pounds (assuming a
standard deviation (SD) of 18.0 pounds) among patients
in the HbA1c test and brief counseling arm who receive
a prediabetes diagnosis (comparable to mean 12-month
weight change and its SD among 387 Veterans who were
referred to a weight loss program in a recent clinical
demonstration project at three VA medical centers [28,
29]) and a projected mean 12-month weight change of
-1.4 pounds (assuming a SD of 13.5 pounds) in the clin-
ical preventive service brochure arm (estimated from a
random sample of VA patients who meet our inclusion
criteria). In order to account for up to 12.5% dropout at
12 months [30] we will inflate our goal sample size for
each of these groups to 63 patients.
Based on local VA data, we conservatively estimate
that 25% of patients who meet our inclusion criteria will
have HbA1c in the prediabetes range. Thus, to achieve
our target of 63 patients with prediabetes in the HbA1c
test and brief counseling arm and 63 patients in the clin-
ical preventive service brochure arm, we will need to use
a 4:1 allocation scheme to randomize 252 patients to the
HbA1c test and brief counseling arm and 63 patients to
the clinical preventive service brochure arm, for a total
sample size of 315 patients.
Statistical analyses
Quantitative analyses
For the primary outcome analysis, we will use the two-
sample t test to evaluate the difference in weight change
between patients who are found to have prediabetes in the
HbA1c test and brief counseling arm and patients in the
clinical preventive service brochure arm who did not re-
ceive an HbA1c test through the study. Additionally, we
will compare baseline measures (e.g., age and body mass
index (BMI)) in these two groups. If we find imbalance in
a baseline measure (defined as P < 0.10 from the F or X2
test), we will adjust for this measure in analyses of
12-month weight change using a mixed-effects model for
longitudinal data rather than the two-sample t test. We
will assess the extent of missing 12-month weight data
and based on this assessment will consider using multiple
imputation for missing data for this outcome. For second-
ary outcomes, we will use data from the baseline, 2-week,
3-month, and 12-month surveys to estimate mixed-effects
regression models that will model mean changes between
patients who are found to have prediabetes in the HbA1c
Table 2 Measures
Category Source Measures
Demographic characteristics VA administrative data at baseline Age and gender
Demographic characteristics Baseline survey Race/ethnicity and education
Health literacy Baseline survey Chew health literacy scale
Patient activation All 4 surveys Patient activation measure
Perception of risk of T2DM All 4 surveys Adriaanse T2DM risk perception scale
Motivation to prevent T2DM All 4 surveys Treatment self-regulation questionnaire
Knowledge of strategies to prevent T2DM All 4 surveys Knowledge of whether weight loss, physical activity, and
pharmacotherapy can prevent T2DM
Self-efficacy to engage in behaviors to
prevent T2DM
All 4 surveys Perceived competence scale for weight loss, increasing
physical activity, taking medication
Physical activity Baseline, 3 month, 12 month surveys Short form of the international physical activity questionnaire
Eating behaviors Baseline, 3 month, 12 month surveys Three-factor eating questionnaire
Engagement in health behaviors related to
T2DM prevention
Surveys at baseline, 3 months,
12 months
(1) Attempting weight loss, (2) taking medication to prevent
T2DM, or (3) participating in a weight-related wellness program
Mental health Surveys at 3 and 12 months Short form health survey (SF-12)
Weight VA administrative data at baseline and
12 months
Weight in pounds
T2DM type 2 diabetes mellitus
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test and brief counseling arm and patients in the clinical
preventive service brochure arm.
Qualitative analyses
We will code semi-structured interview transcripts using
a template analysis approach based on our conceptual
model (Fig. 1) [31]. Three study team members will
independently review a subset of transcripts using modi-
fied grounded theory to identify salient themes [31].
These investigators will discuss the themes, refine them,
and achieve consensus on codes and definitions. Two
study team members will then independently code tran-
scripts in NVivo software. First, they will independently
code the same 20% subset of the transcripts. The un-
weighted Cohen’s kappa statistic will then be calculated
for each response and averaged to provide a single index
of inter-rater reliability. Once excellent agreement is
achieved, these two study team members will divide the
remaining interview transcripts evenly and code these
transcripts separately. The full study team will meet
regularly to discuss code summaries and memos, a
group consensus approach that increases the rigor of
data interpretation and allows documentation of sound
evidence for findings [32].
Discussion
Nearly one in four VA patients has T2DM [33], which is
a leading cause of blindness, amputations, and end-stage
renal disease among Veterans and is associated with a
twofold increase in annual mortality rates. Similarly,
cardiovascular events resulting from T2DM and its asso-
ciated risk factors lead to substantial morbidity and
premature mortality among Veterans. In addition to
these detrimental impacts of T2DM on the health of
Veterans, these conditions contribute substantial costs
within the VHA [34].
One important opportunity to limit these burdens is
to facilitate patients’ engagement in efforts to prevent
T2DM by informing them they have prediabetes and
providing brief counseling with evidence-based recom-
mendations. Such brief interventions have in other clin-
ical settings effectively targeted a range of behavioral
risk factors for chronic disease like cigarette smoking, al-
cohol misuse, and illicit drug use [35–41]. In primary
care clinics, these types of interventions have also shown
promise in promoting physical activity [42] and healthy
dietary practices [43, 44]. A recent systematic review of
brief interventions to promote physical activity and
healthy dietary practices for the US Preventive Services
Task Force found a positive correlation between the in-
tensity and efficacy of these interventions, yet concluded
that many higher-intensity interventions would be in-
feasible to implement in primary care settings [45]. Fur-
ther, few lower-intensity interventions have targeted
high-risk populations or leveraged behavioral science
insights. Irrespective of their intensity, studies of brief
interventions have also rarely reported objectively mea-
sured intermediate outcomes in addition to self-reported
behaviors. As a result, the review concluded that “more
trials are needed to evaluate low-intensity counseling in-
terventions that could be more readily implemented in
primary care” and that such trials should “collect and re-
port objectively measured physiologic outcomes” [45].
In conclusion, an essential step in designing effective
strategies to improve patient engagement in behavior
change is to better understand their current levels of
engagement in these behaviors and determine which
factors influence their engagement. This RCT (SPIRIT
Checklist included as Additional file 3) will generate
foundational data on the effects of a prediabetes diagno-
sis and brief counseling on patients’ preventive behaviors
and mediators of these behaviors. Our future dissemin-
ation of these results in conference proceedings and
peer-reviewed publications will enable the development
of novel strategies to improve patient engagement in
T2DM prevention.
Trial status
The FINDIT study began to recruit patients in December
2015.
Additional files
Additional file 1: Standardized brief phone counseling. (DOCX 65 kb)
Additional file 2: Mailed information about HbA1c results. (DOCX 16 kb)
Additional file 3: SPIRIT checklist. (DOC 113 kb)
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